BioCentury | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

...appointed Adrian Adams as chairman. Adams was CEO at Aralez Pharmaceuticals Inc. and its predecessor Pozen Inc....
BioCentury | Jul 29, 2017
Finance

Show us your shorts

...NASDAQ:ACOR), Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Insys Therapeutics Inc. (NASDAQ:INSY), and Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ; TSX:ARZ) (Pozen Inc....
...and grants Hikma rights to market an authorized generic of Xyrem beginning Jan. 1, 2023 Pozen/Aralez...
BioCentury | Apr 1, 2017
Company News

Management tracks

...CFO. Novan named William Hodges, who was CFO and SVP of finance and administration at Pozen Inc....
BioCentury | Mar 29, 2016
Company News

FDA accepts NDA for Aralez's Yosprala

...325 mg aspirin and PA8140 contains 81 mg aspirin. Aralez was formed last year after Pozen Inc....
BioCentury | Dec 14, 2015
Financial News

Tribute Pharmaceuticals proposes private placement

...Investor: QLT Inc. Note: The completion of the offering and the company’s planned merger with Pozen Inc....
BioCentury | Aug 24, 2015
Company News

Lupin, Pozen autoimmune news

...inter partes review (IPR) petitions with the U.S. Patent and Trademark Office challenging patents from Pozen...
...the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers Pozen...
...6,926,907, which expires in 2023, and the ‘996 patent. Lupin Ltd. (NSE:LUPIN; BSE:500257), Mumbai, India Pozen Inc....
BioCentury | Aug 21, 2015
Company News

Lupin launches IPR challenge against Vimovo

...inter partes review (IPR) petitions with the U.S. Patent and Trademark Office challenging patents from Pozen Inc....
...the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers Pozen...
...of the drug's Orange Book-listed patents. Dr. Reddy%27s filed an IPR petition in February challenging Pozen's...
BioCentury | Jul 28, 2015
Company News

Management tracks

...He was SVP and general manager of diagnostics at NanoString Technologies Inc. (NASDAQ:NSTG). Neurology play Pozen Inc....
...was treasurer and VP of finance at Ikaria Inc. , which Mallinckrodt plc (NYSE:MNK) acquired. Pozen...
...Charles will be CFO of Aralez Pharmaceuticals plc, the company that will be created from Pozen's...
BioCentury | Jul 20, 2015
Company News

Medical Futures, Tribute Pharmaceuticals deal

...period ending March 31, Medical Futures reported about C$10 million ($7.9 million) in net sales. Pozen Inc....
BioCentury | Jun 29, 2015
Company News

Tribute Pharmaceuticals, Pozen deal

...Aralez Pharmaceuticals plc and located in Ireland and will trade on NASDAQ or the TSX. Pozen...
...million ($14.6 million), and Pozen revenues of $32.4 million for the same period. Two of Pozen’s...
...markets several drugs for headache and cardiovascular diseases. Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF;TSX-V:TRX), Milton, Ontario Pozen Inc....
Items per page:
1 - 10 of 403
BioCentury | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

...appointed Adrian Adams as chairman. Adams was CEO at Aralez Pharmaceuticals Inc. and its predecessor Pozen Inc....
BioCentury | Jul 29, 2017
Finance

Show us your shorts

...NASDAQ:ACOR), Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Insys Therapeutics Inc. (NASDAQ:INSY), and Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ; TSX:ARZ) (Pozen Inc....
...and grants Hikma rights to market an authorized generic of Xyrem beginning Jan. 1, 2023 Pozen/Aralez...
BioCentury | Apr 1, 2017
Company News

Management tracks

...CFO. Novan named William Hodges, who was CFO and SVP of finance and administration at Pozen Inc....
BioCentury | Mar 29, 2016
Company News

FDA accepts NDA for Aralez's Yosprala

...325 mg aspirin and PA8140 contains 81 mg aspirin. Aralez was formed last year after Pozen Inc....
BioCentury | Dec 14, 2015
Financial News

Tribute Pharmaceuticals proposes private placement

...Investor: QLT Inc. Note: The completion of the offering and the company’s planned merger with Pozen Inc....
BioCentury | Aug 24, 2015
Company News

Lupin, Pozen autoimmune news

...inter partes review (IPR) petitions with the U.S. Patent and Trademark Office challenging patents from Pozen...
...the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers Pozen...
...6,926,907, which expires in 2023, and the ‘996 patent. Lupin Ltd. (NSE:LUPIN; BSE:500257), Mumbai, India Pozen Inc....
BioCentury | Aug 21, 2015
Company News

Lupin launches IPR challenge against Vimovo

...inter partes review (IPR) petitions with the U.S. Patent and Trademark Office challenging patents from Pozen Inc....
...the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers Pozen...
...of the drug's Orange Book-listed patents. Dr. Reddy%27s filed an IPR petition in February challenging Pozen's...
BioCentury | Jul 28, 2015
Company News

Management tracks

...He was SVP and general manager of diagnostics at NanoString Technologies Inc. (NASDAQ:NSTG). Neurology play Pozen Inc....
...was treasurer and VP of finance at Ikaria Inc. , which Mallinckrodt plc (NYSE:MNK) acquired. Pozen...
...Charles will be CFO of Aralez Pharmaceuticals plc, the company that will be created from Pozen's...
BioCentury | Jul 20, 2015
Company News

Medical Futures, Tribute Pharmaceuticals deal

...period ending March 31, Medical Futures reported about C$10 million ($7.9 million) in net sales. Pozen Inc....
BioCentury | Jun 29, 2015
Company News

Tribute Pharmaceuticals, Pozen deal

...Aralez Pharmaceuticals plc and located in Ireland and will trade on NASDAQ or the TSX. Pozen...
...million ($14.6 million), and Pozen revenues of $32.4 million for the same period. Two of Pozen’s...
...markets several drugs for headache and cardiovascular diseases. Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF;TSX-V:TRX), Milton, Ontario Pozen Inc....
Items per page:
1 - 10 of 403